Arbutus Biopharma Corporation
| NASDAQ: ABUS | Healthcare / Biotechnology / USA |
| 1.90 | +0.0500 | +2.70% | Vol 989.39K | 1Y Perf -22.59% |
| Nov 29th, 2023 16:00 DELAYED |
| BID | 1.84 | ASK | 1.92 | ||
| Open | 1.87 | Previous Close | 1.85 | ||
| Pre-Market | - | After-Market | 1.94 | ||
| - - | 0.04 2.11% |
| Target Price | 5.67 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 198.42 | Finscreener Ranking | ★★★★★ 58.92 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★+ 54.04 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★★+ 60.81 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 14.43 | Earnings Rating | Strong Buy | |
| Market Cap | 318.62M | Earnings Date | 7th Nov 2023 | |
| Alpha | 0.00 | Standard Deviation | 0.27 | |
| Beta | 1.92 |
Today's Price Range 1.871.94 | 52W Range 1.693.15 | 5 Year PE Ratio Range -2.40-1.10 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 0.54% | ||
| 1 Month | 6.94% | ||
| 3 Months | -8.87% | ||
| 6 Months | -26.00% | ||
| 1 Year | -22.59% | ||
| 3 Years | -57.37% | ||
| 5 Years | -61.22% | ||
| 10 Years | -77.30% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -114.89 | |||
ROE last 12 Months | -116.28 | |||
ROA (5Y Avg) | -33.88 | |||
ROA last 12 Months | -40.35 | |||
ROC (5Y Avg) | -1 038.08 | |||
ROC last 12 Months | -114.78 | |||
Return on invested Capital Q | -11.75 | |||
Return on invested Capital Y | -29.68 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 25.10 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -5.20 | ||||
| 2.72 | ||||
| 12.83 | ||||
| 7.67K | ||||
| -21.10 | ||||
| -0.26 | ||||
| 2.72 | ||||
| 0.92 | ||||
| 262.92M | ||||
| Forward PE | -4.79 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.00 | ||||
| 5.10 | ||||
| 0.01 | ||||
| 0.02 | ||||
| -31.80 | ||||
| Leverage Ratio | 1.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -22.60 | ||||
| -173.50 | ||||
| -169.20 | ||||
| -1 280.60 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 32.77M | ||||
| 0.21 | ||||
| 34.35 | ||||
| 30.97 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | -0.12 | -0.12 | 0.00 |
| Q02 2023 | -0.12 | -0.10 | 16.67 |
| Q01 2023 | -0.14 | -0.10 | 28.57 |
| Q04 2022 | -0.14 | -0.14 | 0.00 |
| Q03 2022 | -0.12 | -0.12 | 0.00 |
| Q02 2022 | -0.13 | -0.10 | 23.08 |
| Q01 2022 | -0.13 | -0.11 | 15.38 |
| Q04 2021 | -0.16 | -0.15 | 6.25 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2023 QR | -0.12 | 0.00 | - |
| 12/2023 FY | -0.45 | -4.65 | Negative |
| 3/2024 QR | -0.10 | 16.67 | Positive |
| 12/2024 FY | -0.39 | 20.41 | Positive |
| Next Report Date | - |
| Estimated EPS Next Report | -0.12 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 989.39K |
| Shares Outstanding | 167.70K |
| Shares Float | 119.23M |
| Trades Count | 2.66K |
| Dollar Volume | 1.88M |
| Avg. Volume | 665.96K |
| Avg. Weekly Volume | 691.67K |
| Avg. Monthly Volume | 678.33K |
| Avg. Quarterly Volume | 627.88K |
Arbutus Biopharma Corporation (NASDAQ: ABUS) stock closed at 1.85 per share at the end of the most recent trading day (a 0.54% change compared to the prior day closing price) with a volume of 538.01K shares and market capitalization of 318.62M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 80 people. Arbutus Biopharma Corporation CEO is William H. Collier.
The one-year performance of Arbutus Biopharma Corporation stock is -22.59%, while year-to-date (YTD) performance is -20.6%. ABUS stock has a five-year performance of -61.22%. Its 52-week range is between 1.69 and 3.145, which gives ABUS stock a 52-week price range ratio of 14.43%
Arbutus Biopharma Corporation currently has a PE ratio of -5.20, a price-to-book (PB) ratio of 2.72, a price-to-sale (PS) ratio of 12.83, a price to cashflow ratio of 7 665.10, a PEG ratio of -, a ROA of -40.35%, a ROC of -114.78% and a ROE of -116.28%. The company’s profit margin is -%, its EBITDA margin is -169.20%, and its revenue ttm is $32.77 Million , which makes it $0.21 revenue per share.
Of the last four earnings reports from Arbutus Biopharma Corporation, there were 2 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.12 for the next earnings report. Arbutus Biopharma Corporation’s next earnings report date is -.
The consensus rating of Wall Street analysts for Arbutus Biopharma Corporation is Strong Buy (1), with a target price of $5.67, which is +198.42% compared to the current price. The earnings rating for Arbutus Biopharma Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Arbutus Biopharma Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Arbutus Biopharma Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 13.39, ATR14 : 0.09, CCI20 : 11.57, Chaikin Money Flow : 0.28, MACD : 0.00, Money Flow Index : 41.20, ROC : -1.07, RSI : 50.86, STOCH (14,3) : 55.56, STOCH RSI : 0.47, UO : 64.01, Williams %R : -44.44), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Arbutus Biopharma Corporation in the last 12-months were:
Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops and commercializes cure for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and also involved in licensing of Lipid nanoparticle technology.
CEO: William H. Collier
Telephone: +1 267 469-0914
Address: 701 Veterans Circle, Warminster 18974, PA, US
Number of employees: 80
TipRanks News for ABUS
Fri, 10 Nov 2023 11:01 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (DOCS), Arbutus Biopharma (ABUS) and Bluebird Bio (BLUE)
- TipRanks. All rights reserved.
